"Innovation disclosed last week that the Company signed a Material Transfer Agreement (MTA) to provide Brilacidin to one of the U.S.’s 12 Regional Biocontainment Labs (RBLs) for evaluation against COVID-19.
Today, the Company announces that a second MTA has been signed to ship Brilacidin to a major U.S. university for analysis."
Isn't that a third MTA or did something happen to this?
"WAKEFIELD, MA – February 24, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company submitted a Material Transfer Agreement (MTA) with a leading U.S.-based virology laboratory to research its lead defensin mimetic drug candidate, Brilacidin, as a potential novel coronavirus treatment."